Constantine Davides
Stock Analyst at EF Hutton
(0.53)
# 2,804
Out of 4,225 analysts
47
Total ratings
18.37%
Success rate
-36.01%
Average return
Main Sectors:
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NMRD Nemaura Medical | Maintains: Buy | $6 → $4 | $0.23 | +1,639.13% | 4 | Jul 17, 2023 | |
| NNVC NanoViricides | Assumes: Buy | $5 | $1.17 | +348.72% | 3 | Jun 1, 2023 | |
| MEDS TRxADE HEALTH | Maintains: Buy | $26 → $19 | $5.65 | +231.86% | 2 | May 16, 2023 | |
| LGVN Longeveron | Reiterates: Buy | $13 | $1.95 | +541.03% | 5 | May 16, 2023 | |
| ELMD Electromed | Reiterates: Buy | $15 | $10.25 | +46.34% | 3 | May 11, 2023 | |
| INVA Innoviva | Reiterates: Buy | $23 | $13.69 | +64.35% | 4 | May 10, 2023 | |
| CCLD CareCloud | Reiterates: Buy | $9 | $1.02 | +733.33% | 2 | May 5, 2023 | |
| HOTH Hoth Therapeutics | Reiterates: Buy | $14 | $1.14 | +1,128.07% | 4 | Apr 27, 2023 | |
| HCWB HCW Biologics | Reiterates: Buy | $9 | $1.09 | +725.69% | 4 | Apr 19, 2023 | |
| BBLG Bone Biologics | Reiterates: Buy | $68 | $0.41 | +16,243.83% | 3 | Apr 13, 2023 | |
| KTTA Pasithea Therapeutics | Maintains: Buy | $2 → $2 | $0.35 | +464.97% | 2 | Apr 3, 2023 | |
| VNRX VolitionRx | Reiterates: Buy | $6 | $0.77 | +679.22% | 2 | Mar 16, 2023 | |
| ACST Acasti Pharma | Reiterates: Buy | $15 | $2.05 | +631.71% | 2 | Feb 15, 2023 | |
| BIVI BioVie | Maintains: Buy | $14 → $8 | $1.96 | +308.16% | 2 | Sep 28, 2022 | |
| HCTI Healthcare Triangle | Maintains: Buy | $40 → $20 | $3.88 | +415.46% | 2 | Sep 28, 2022 | |
| ISPC iSpecimen | Maintains: Buy | $6 → $4 | $0.56 | +658.93% | 2 | Sep 23, 2022 | |
| TCBP TC Biopharm (Holdings) | Initiates: Buy | $2,500 | $0.38 | +656,067.98% | 1 | Mar 28, 2022 |